ScripsAmerica's Pharmaceutical Joint Venture Generates Record Revenue in December

TYSONS CORNER, Va., Jan. 6, 2014 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (OTCBB:SCRC) today announced that the Company received and processed a record high $165,424 in orders from its pharmaceutical distribution joint venture (JV) during the month of December.

December's revenue puts ScripsAmerica's JV on a run rate of $2 million and the Company expects to see continued growth as it begins 2014. Since its formation in August of 2013, revenue generated from the Company's JV, which provides independent pharmacies with wholesale prescription drugs, has shown consistent monthly growth.

ScripsAmerica's CEO, Bob Schneiderman, stated, "The company is very pleased to close last year with a record setting month for our pharmaceutical joint venture. Our growth in this business area has been very impressive with monthly revenue increasing from approximately $63,000 to over $165,000 in less than two quarters. ScripsAmerica looks forward to expanding the scope of our wholesale pharmaceutical distribution operations in 2014 and anticipates increased shareholder revenue as a result."

About ScripsAmerica, Inc.

ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: 888-959-7095 ir@sealpointconsulting.comSource:ScripsAmerica, Inc.